Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy

Am J Hematol. 2021 May 1;96(5):E157-E162. doi: 10.1002/ajh.26125. Epub 2021 Feb 23.

Authors

Kitsada Wudhikarn¹, Leslie Padrnos², Terra Lasho¹, Betsy LaPlant², Shaji Kumar¹, Angela Dispenzieri¹, Martha Lacy¹, S Vincent Rajkumar¹, Morie Gertz¹, Abhishek A Mangaonkar¹, Wilson Gonsalves¹, Rhett Ketterling³, Chang-Xin Shi², Rafael Fonseca², A Keith Stewart², Mrinal M Patnaik¹

Affiliations

¹ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
² Division of Hematology-Oncology, Mayo Clinic, Phoenix, Arizona.
³ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

PMID: 33580975
DOI: 10.1002/ajh.26125

No abstract available

Publication types

Letter

MeSH terms

Aged
Clonal Hematopoiesis*
Female
Hematopoietic Stem Cell Transplantation
Humans
Immunologic Factors / administration & dosage
Immunologic Factors / adverse effects
Immunologic Factors / therapeutic use*
Lenalidomide / administration & dosage
Lenalidomide / adverse effects
Lenalidomide / therapeutic use*
Maintenance Chemotherapy
Male
Melphalan / therapeutic use
Middle Aged
Multiple Myeloma / drug therapy
Multiple Myeloma / genetics
Multiple Myeloma / physiopathology*
Multiple Myeloma / therapy
Prognosis
Retrospective Studies
Salvage Therapy
Transplantation Conditioning
Transplantation, Autologous
Venous Thrombosis / chemically induced
Venous Thrombosis / etiology

Substances

Immunologic Factors
Lenalidomide
Melphalan